comscore2015 San Antonio Breast Cancer Symposium: Arimidex, Tamoxifen, and Recurrence Risk After DCIS

2015 San Antonio Breast Cancer Symposium: Arimidex, Tamoxifen, and Recurrence Risk After DCIS

Marisa Weiss, MD, Breastcancer.org chief medical officer, explains a study looking at Arimidex and tamoxifen for reducing risk after DCIS surgery.
Oct 19, 2016
00:00
Download
00:00

In this podcast, Dr. Marisa Weiss explains a study that looked at the effectiveness of Arimidex and tamoxifen for reducing risk after DCIS surgery and radiation, as well as the side effects of each medicine. The study was presented at the 2015 San Antonio Breast Cancer Symposium, December 8-12.

Listen to the podcast to hear Dr. Weiss explain:

  • what DCIS is

  • why postmenopausal women should be reassured no matter which of these medicines they’re taking

  • the side effects of each medicine

About the guest
 
Marisa Weiss headshot
Marisa C. Weiss, MD

Dr. Weiss is regarded as a visionary advocate for her innovative and steadfast approach to informing individuals to protect their breast health and overcome the challenges of breast cancer. Dr. Weiss currently practices at Lankenau Medical Center, where she serves as director of breast radiation oncology and director of breast health outreach. Learn more.

— Last updated on May 2, 2022, 2:44 PM

 
Lilly Oncology

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate